Sotatercept as an Add-On to Background Therapy in Idiopathic Pulmonary Arterial Hypertension: Insights from a Real-World Cohort

<b>Background</b>: Sotatercept, a first-in-class activin-signaling inhibitor, demonstrated efficacy in pulmonary arterial hypertension (PAH) in the pivotal PULSAR and STELLAR trials. However, whether these benefits and the drug’s distinct safety profile translate to routine clinical practice in the...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Charalampos Filippatos, Ioannis Boutsikos, Nikolaos-Iason Tepetes, Andrew Xanthopoulos, Ernesto Ruiz Duque, Rabea Asleh, George Giannakoulas, Alexandros Briasoulis
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	MDPI AG 2026-05-01
Σειρά:	Pharmaceuticals
Θέματα:	idiopathic pulmonary arterial hypertension PAH sotatercept background therapy
Διαθέσιμο Online:	https://www.mdpi.com/1424-8247/19/5/760
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!